Scribe's STX-1150, a single-dose CRISPR-based epigenetic therapy, achieved sustained LDL-C reductions exceeding 50% for over 22 months in preclinical models, with no permanent DNA changes. The approach targets hepatic PCSK9 expression through transient mRNA delivery, advancing toward human trials as an alternative to chronic pharmacotherapy.
Key Points
- Single dose produced >50% LDL-C reduction sustained 22+ months
- PCSK9 downregulation reached ~90% in non-human primates
- Safety profile favorable; no off-target gene expression detected
Longevity Analysis
Sustained reduction in circulating lipid levels directly correlates with extended healthspan by mitigating atherosclerotic progression and endothelial dysfunction. Single-dose durability addresses a fundamental problem in cardiovascular risk management: the burden of chronic medication adherence and its consequences for long-term compliance. By transiently modulating hepatic gene expression without permanent genomic integration, this approach eliminates a primary concern with permanent genetic modification while maintaining therapeutic effect duration that spans years—creating a mechanistic bridge between acute intervention and durable outcome that conventional therapeutics have not achieved.
Original published by Longevity.Technology.